SEC Tracker
Get the app
IDXG · XBRL financial data

Interpace Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (IDXG's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Nov 7, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers9,07810,283*10,27312,04212,29512,316*11,5159,232—9,224*9,0329,131
Cost of revenue4,1244,147*4,2024,6114,7893,399*4,1453,956—3,180*3,1283,478
Gross profit4,9546,136*6,0717,4317,5068,917*7,3705,276—6,044*5,9045,653
Research and development149152*137146199193*177173—142*153149
General and administrative2,1241,848*2,2392,1412,5382,568*2,5502,661—2,212*2,4512,976
Total operating expenses4,9704,823*5,1975,1745,6015,845*5,5415,744—4,467*4,7815,332
Other operating income (expense)——(82)71(394)(93)*21(16)—(30)*109
Operating income (loss)(16)1,313*8742,2571,9053,072*1,829(468)—1,577*1,123321
Interest expense——197176141—7849————
Other income (expense)(252)(259)*(82)7110—7(10)——109
Income tax expense (benefit)45*444(8)*180*—(21,217)*30264
Net income (loss)(614)890*4682,0621,2802,892*1,647(640)—22,657*721158
Earnings per share, basic USD per share(0.14)—0.110.470.29—0.37(0.14)—5.12*0.030.01
Earnings per share, diluted USD per share(0.14)—0.110.470.29—0.06(0.14)——0.030.01
Weighted average shares, basic thousands of shares4,3194,331*4,3704,3764,3934,409*4,4204,423—4,428*22,78627,701
Weighted average shares, diluted thousands of shares4,3194,511*4,3844,4014,423—27,7044,423——27,70727,713

Balance sheet

CSV

Fiscal quarters (IDXG's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Nov 7, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents5,0323,4982,8122,0192,1131,4611,1965022,1002,5052,6472,688
Accounts receivable4,8304,9835,0066,2067,2938,5448,7687,231—5,6495,9256,311
Inventory1,0931,2271,1541,2311,2201,2111,209973—1,1149611,085
Total current assets11,43810,3229,41610,16611,11011,77311,6549,504—9,9009,96310,968
Property and equipment, net7627909251,1261,3521,3611,2771,366—1,4231,3151,621
Right-of-use asset1,9781,8641,7561,6351,5321,6131,5181,420—1,2171,1101,001
Total assets14,25013,02112,14212,97214,03914,79214,49412,335—33,83833,40934,549
Accounts payable1,3521,5441,3631,7611,7011,6591,7331,250—9838051,555
Total current liabilities12,32417,47418,97319,03018,76910,6158,6787,149—5,1033,9624,951
Lease liability, non-current1,5561,4721,3591,2861,1891,1831,080974—752635516
Total liabilities30,39428,15726,74725,46225,18517,00915,07613,548—11,47510,32711,305
Accumulated deficit(249,105)(248,215)(247,747)(245,685)(244,405)(235,380)(233,733)(234,373)—(210,805)(210,084)(209,926)
Total stockholders' equity(62,680)(61,672)(61,141)(59,026)(57,682)(2,217)(582)(1,213)—22,36323,08223,244
Total liabilities and equity14,25013,02112,14212,97214,03914,79214,49412,335—33,83833,40934,549
Common shares outstanding (cover page) thousands of shares4,3224,3764,3764,3944,4054,4234,4234,4234,42927,70127,70127,701

Cash flows

CSV

Fiscal quarters (IDXG's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Nov 7, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(614)890*4682,0621,2802,892*1,647(640)—22,657*721158
Stock-based compensation152*129*7953*86*73*159—4*44
Depreciation and amortization240*72*5267*86*95*95101*—118*118127*
Net cash from operating activities1,105*1,140*(58)1,404*2,116*1,184*1,235520*—2,138*28398*
Purchases of property and equipment152*142*28197*522*129*———38*14157*
Net cash from investing activities348*(142)*(28)(197)*(522)*(129)*———(38)*(141)(57)*
Net cash from financing activities(1,500)*(2,532)*(600)(2,000)*(1,500)*(1,707)*(1,500)(1,013)*—(1,018)*——
Net change in cash(47)*(1,534)*(686)(793)*94*(652)*(265)(694)*—1,082*14241*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Interpace Biosciences2,6889,13198*27.7M— 10-QJun 30, 2026
Global Innovative Platforms24451(134)*49.8M1.8 quarters 10-QJun 30, 2026
ENDRA Life Sciences1,740not reported(928)*1.5M1.9 quarters 10-QJun 30, 2026
Bluejay Diagnostics9,599not reported(1,499)*4.5M6.4 quarters 10-QJun 30, 2026
Stimcell Energetics6.9not reported(109)21.1M0.1 quarters 10-QAug 31, 2026
LogicMark3,4963,34983*899,759— 10-QJun 30, 2026
INVO Fertility3,7332,175(1,101)*2.5M3.4 quarters 10-QJun 30, 2026
Semler Scientific10,1767,491(32,950)*15.2M0.3 quarters 10-QSep 30, 2025
Nu-Med Plus5.401.1*83.5M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.